BioTelemetry’s (BEAT) “Buy” Rating Reiterated at Dougherty & Co

Dougherty & Co reissued their buy rating on shares of BioTelemetry, Inc. (NASDAQ:BEAT) in a report issued on Wednesday. Dougherty & Co currently has a $40.00 price target on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on BEAT. Sidoti restated a buy rating and issued a $49.00 price target (up from $42.00) on shares of BioTelemetry in a research note on Thursday, August 10th. BidaskClub upgraded shares of BioTelemetry from a buy rating to a strong-buy rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded shares of BioTelemetry from a hold rating to a strong-buy rating and set a $39.00 price target on the stock in a research note on Friday, August 11th. Raymond James Financial, Inc. assumed coverage on shares of BioTelemetry in a research note on Thursday, October 26th. They issued an outperform rating and a $37.00 price target on the stock. Finally, Lake Street Capital restated a buy rating and issued a $50.00 price target (up from $35.00) on shares of BioTelemetry in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. BioTelemetry presently has a consensus rating of Buy and a consensus price target of $42.86.

BioTelemetry (BEAT) traded down $0.40 on Wednesday, hitting $24.30. 546,700 shares of the stock were exchanged, compared to its average volume of 472,275. BioTelemetry has a one year low of $17.27 and a one year high of $39.20. The company has a current ratio of 1.60, a quick ratio of 1.91 and a debt-to-equity ratio of 0.75. The firm has a market cap of $800.48, a P/E ratio of 33.84, a P/E/G ratio of 1.40 and a beta of 0.58.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The company had revenue of $81.02 million during the quarter, compared to analyst estimates of $82.10 million. During the same quarter in the previous year, the business posted $0.21 earnings per share. The company’s revenue for the quarter was up 52.7% on a year-over-year basis. equities analysts predict that BioTelemetry will post 0.92 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://stocknewstimes.com/2017/11/11/biotelemetrys-beat-buy-rating-reiterated-at-dougherty-co.html.

A number of large investors have recently bought and sold shares of BEAT. Winslow Evans & Crocker Inc. acquired a new stake in BioTelemetry during the 3rd quarter worth approximately $109,000. Pinebridge Investments L.P. boosted its position in BioTelemetry by 2.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after buying an additional 75 shares during the period. Victory Capital Management Inc. boosted its position in BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after buying an additional 626 shares during the period. Dubuque Bank & Trust Co. acquired a new stake in BioTelemetry during the 2nd quarter worth approximately $142,000. Finally, US Bancorp DE acquired a new stake in BioTelemetry during the 2nd quarter worth approximately $145,000. Institutional investors and hedge funds own 77.76% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply